· MEDIPOST assessed the safety and tolerability of single injections in different doses in patients with mild to moderate knee osteoarthritis
· The company expects to report the clinical results and begin the next phase of the clinical trial in the first half of the upcoming year

MEDIPOST announced on the 16th that the company has completed the phase 1 clinical trial conducted in Korea. The trial assessed the company’s injectable drug for knee osteoarthritis (SMUP-IA-01) that was developed with SMUP-Cell, the next-generation stem cell culture platform.

The phase 1 clinical trial was a single-center trial conducted at Seoul National University Hospital to evaluate the safety and potential efficacy in 12 patients with mild to moderate knee osteoarthritis (K&L Grade 2 to 3).

After the patients with knee osteoarthritis were given a single injection into their knee joint cavity in different doses, safety and tolerability were investigated to determine the maximum tolerated dose (MTD).

MEDIPOST’s injectable drug for knee osteoarthritis (SMUP-IA-01) is the first treatment developed by MEDIPOST using the company’s proprietary stem cell therapy platform, SMUP-Cell.

The SMUP-Cell technology selects small high-efficiency stem cells, which allows mass production through bioreactors. Also, the drug’s final formulation consists of a frozen formulation with easier storage and transport capabilities. This allows easier exports with extended expiration dates and reduced transportation costs.

An officer of MEDIPOST said, “Our injectable drug for knee osteoarthritis (SMUP-IA-01) was developed for patients with mild to moderate knee osteoarthritis (K&L Grade 2–3) that do not require surgery. A single injection can improve knee pain and function, and in the long run, we expect the drug to improve the joint structure.” He added, “We also plan to report the clinical results in the first half of next year and start the next phase of the clinical trials as quickly as possible.